These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 6612677)

  • 1. Effects of ketanserin and mepyramine on platelet aggregation and on the uptake of 5-hydroxytryptamine into platelets.
    Bevan J; Heptinstall S
    Thromb Res; 1983 Jun; 30(5):415-23. PubMed ID: 6612677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of ketanserin, a selective 5-HT2 serotonergic antagonist, on the secondary recruitment of human platelets in vitro.
    De Clerck F; Xhonneux B
    Agents Actions; 1986 Mar; 17(5-6):515-26. PubMed ID: 2939698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serotonin-induced platelet aggregation in whole blood and the effects of ketanserin and mepyramine.
    Bevan J; Heptinstall S
    Thromb Res; 1985 Apr; 38(2):189-94. PubMed ID: 3159127
    [No Abstract]   [Full Text] [Related]  

  • 4. Inhibition of 5-hydroxytryptamine-induced and -amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT2-receptor antagonist.
    de Clerck F; David JL; Janssen PA
    Agents Actions; 1982 Jul; 12(3):388-97. PubMed ID: 6215842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous inhibition of platelet S2-serotonergic receptors during chronic administration of ketanserin in humans.
    De Clerck F; Xhonneux B
    J Cardiovasc Pharmacol; 1985; 7 Suppl 7():S23-5. PubMed ID: 2412050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet deactivation by 5HT2-receptor blockade parallels the antihypertensive response to ketanserin.
    Amstein R; Fetkovska N; Pletscher A; Bühler FR
    J Hypertens; 1989 Apr; 7(4):255-60. PubMed ID: 2723427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5HT2-receptors and serotonin release: their role in human platelet aggregation.
    Cerrito F; Lazzaro MP; Gaudio E; Arminio P; Aloisi G
    Life Sci; 1993; 53(3):209-15. PubMed ID: 8321084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effects of ketanserin, a novel serotonergic receptor antagonist, on 5HT-induced shape change and 5HT uptake in rat and human platelets.
    Lampugnani MG; de Gaetano G
    Biochem Pharmacol; 1982 Sep; 31(18):3000-2. PubMed ID: 7138588
    [No Abstract]   [Full Text] [Related]  

  • 9. The involvement of 5-HT2-receptor sites in the activation of cat platelets.
    De Clerck F; Xhonneux B; Leysen J; Janssen PA
    Thromb Res; 1984 Feb; 33(3):305-21. PubMed ID: 6710435
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamics of platelet mobilisation into lungs in response to 5-hydroxytryptamine (serotonin) in mice.
    Yu Z; Ohba M; Nakamura M; Sasano T; Ono M; Sugawara S; Endo Y
    Thromb Haemost; 2009 Dec; 102(6):1251-8. PubMed ID: 19967158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenosine diphosphate induced platelet aggregation and release reaction in heparinized platelet rich plasma and the influence of added citrate.
    Heptinstall S; Mulley GP
    Br J Haematol; 1977 Aug; 36(4):565-71. PubMed ID: 889719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Age, platelet serotonin kinetics and 5HT2-receptor blockade in essential hypertension.
    Amstein R; Fetkovska N; Bühler FR
    J Hum Hypertens; 1990 Aug; 4(4):441-4. PubMed ID: 2258891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of serotonin-amplified human platelet aggregation by ketanserin, ritanserin, and the ergoline 5HT2 receptor antagonists-LY53857, sergolexole, and LY237733.
    McBride PA; Mann JJ; Nimchinsky E; Cohen ML
    Life Sci; 1990; 47(23):2089-95. PubMed ID: 2125095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potentiation of ADP-induced aggregation in human platelet-rich plasma by 5-hydroxytryptamine and adrenaline.
    Vanags DM; Rodgers SE; Duncan EM; Lloyd JV; Bochner F
    Br J Pharmacol; 1992 Aug; 106(4):917-23. PubMed ID: 1393289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Verapamil, an antagonist at 5-hydroxytryptamine receptors of human blood platelets.
    Affolter H; Burkard WP; Pletscher A
    Eur J Pharmacol; 1985 Jan; 108(2):157-62. PubMed ID: 3156755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urapidil inhibits 5-hydroxytryptamine induced platelet aggregation and 14C-5-hydroxytryptamine uptake in platelets.
    Storck J; Kirsten R
    Curr Med Res Opin; 1990; 12(2):86-92. PubMed ID: 2390867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of 5-hydroxytryptamine-potentiated aggregation of human blood platelets by 5-hydroxytryptamine receptor-blocking agents.
    Glusa E; Markwardt F
    Biomed Biochim Acta; 1984; 43(2):215-20. PubMed ID: 6732757
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dependence of the antagonism at human platelet 5-HT2 receptors by ketanserin on the reaction pH.
    De Clerck F; Xhonneux B; Tollenaere JP; Janssen PA
    Thromb Res; 1985 Dec; 40(5):581-96. PubMed ID: 2935970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of urapidil on 5-hydroxytryptamine induced platelet aggregation and on 14C-5-hydroxytryptamine uptake in platelets.
    Storck J; Ochs JG; Kirsten R
    Int J Clin Pharmacol Ther Toxicol; 1990 Jul; 28(7):303-8. PubMed ID: 2387654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Involvement of platelet-derived 5-hydroxytryptamine in thromboxane A2-induced aggregation in cat platelets.
    Ogawa T; Sugidachi A; Asai F; Koike H
    Blood Coagul Fibrinolysis; 1998 Apr; 9(3):233-40. PubMed ID: 9663705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.